Elanco Animal Health (ELAN) Long-Term Investments (2017 - 2018)
Elanco Animal Health (ELAN) posted Long-Term Investments of $15.3 million for Q4 2018, up 2.68% sequentially from $14.9 million in Q3 2018, and up 24.39% YoY from $12.3 million in Q4 2017.
Elanco Animal Health (ELAN) Long-Term Investments (2017 - 2018) Analysis & Trends
Elanco Animal Health has reported Long-Term Investments for 2 years, with the latest figure at $15.3 million in Q4 2018.
- Quarterly Long-Term Investments rose 24.39% year-over-year to $15.3 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $15.3 million (up 24.39% YoY) and the FY2018 annual result came in at $15.3 million, up 24.39% from the prior year.
- Long-Term Investments advanced to $15.3 million in Q4 2018 per ELAN's latest filing, from $14.9 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $15.3 million in Q4 2018 and troughed at $12.3 million in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 92.58 Mn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 63.23 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 1.14 Bn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 149.10 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | 60.00 Mn |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | 35.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 15.30 Mn |
| Sep 30, 2018 | 14.90 Mn |
| Dec 31, 2017 | 12.30 Mn |